Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

229.11USD
9:00pm BST
Change (% chg)

$-5.93 (-2.52%)
Prev Close
$235.04
Open
$232.94
Day's High
$233.22
Day's Low
$227.46
Volume
854,346
Avg. Vol
758,941
52-wk High
$388.67
52-wk Low
$216.13

Select another date:

Wed, May 15 2019

Photo

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

UPDATE 3-Biogen dips as strategy post Alzheimer's setback fails to impress

* Co beats 1st-qtr profit and revenue estimates (Adds details from conference call, analyst comment)

Biogen first-quarter profit rises 20 percent

April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.

Select another date: